Table 3.
Assay Performance - Coefficients and Variantion and Interclass Correlation Coefficients by Anti-EBV ELISA Serology Test - EBV Serology Reproducibility Studya
| Assay | # Individuals Tested | % Agreementc | Within Batch | Across Batch | Overall | |
|---|---|---|---|---|---|---|
| CV | CV | CV | ICC | |||
| EBNA IgA | 97 | 89.7% | 11.0 | 6.8 | 12.9 | 78.1 |
| VCAp18 IgA | 97 | 88.7% | 7.3 | 5.8 | 9.4 | 87.7 |
| EA ext IgAb | 97 | 87.6% | 13.0 | 10.9 | 17.0 | 42.3 |
| EAp138 IgA | 97 | 87.6% | 10.0 | 2.0 | 10.2 | 73.3 |
| EAd IgAb | 97 | 90.7% | 10.6 | 5.1 | 11.8 | 73.9 |
| Zebra IgA | 97 | 89.7% | 9.1 | 8.6 | 12.5 | 67.1 |
| EA ext IgGb | 97 | 82.1% | 7.0 | 8.2 | 10.8 | 65.3 |
| EAp138 IgG | 97 | 81.1% | 10.5 | 5.3 | 11.8 | 74.6 |
| EAd IgG | 97 | 90.0% | 12.6 | 6.6 | 14.2 | 71.3 |
| Zebra IgG | 97 | 85.2% | 8.5 | 4.5 | 9.6 | 82.0 |
a
Random effect in the mixed models included testing date, box, and repeated aliquots of the same person; study group (defined by NPC and EBV antibody status) was included as a fixed effect.
b
Models including “testing date” as a random effect did not converge; “test day” (coded as 1 or 2) was included as a fixed effect instead.
c
Agreement based on dichotomous results of each assay as described in the Methods